
Sana Biotechnology (SANA) Stock Forecast & Price Target
Sana Biotechnology (SANA) Analyst Ratings
Bulls say
Sana Biotechnology is positioned favorably with a growth rate in biologics usage of 32% from 2022 to 2023, indicating a robust demand for innovative therapies in both the US and EU5 markets. The company’s focus on engineered cell therapies, coupled with the anticipated increased accessibility and lower costs of candidates like SG299, suggests potential for greater market uptake, particularly in challenging therapeutic areas such as systemic lupus erythematosus (SLE) and lupus nephritis (LN). Furthermore, the reported 40% increase in biologics usage among patients initiating or switching treatments underscores the expanding acceptance and integration of biologics within clinical practice, further bolstering the outlook for Sana’s therapeutic pipeline.
Bears say
Sana Biotechnology Inc faces significant challenges regarding the efficacy and safety of its lead programs, raising concerns about their potential to advance through clinical development successfully. The association of certain conditions, such as lupus nephritis (LN) and Type 1 diabetes (T1D), with poor prognoses—including high rates of kidney failure and elevated morbidity—places additional pressure on the company’s ability to demonstrate effective treatment outcomes. These factors contribute to a negative outlook, as the potential for halted development due to safety signals or ineffectiveness could hinder the company's ability to capitalize on unmet treatment needs in their targeted therapeutic areas.
This aggregate rating is based on analysts' research of Sana Biotechnology and is not a guaranteed prediction by Public.com or investment advice.
Sana Biotechnology (SANA) Analyst Forecast & Price Prediction
Start investing in Sana Biotechnology (SANA)
Order type
Buy in
Order amount
Est. shares
0 shares